BC Extra | Jun 21, 2019
Company News

June 20 Company Quick Takes: Priority Review for Alexion, Melinta therapies; plus Alimera, Denovo and more

Priority Review for Alexion's Ultomiris sBLA  FDA accepted and granted Priority Review to an sBLA from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) for Ultomiris ravulizumab-cwvz to block complement-mediated thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome....
BC Week In Review | Apr 13, 2018
Company News

pSivida acquires Icon, rebrands to EyePoint

EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT; ASX:PVA) (formerly pSivida Corp.) acquired Icon Bioscience Inc. (Newark, Calif.) and rebranded under a new name and ticker. EyePoint gained Icon's Dexycu dexamethasone intraocular suspension 9%, which received FDA approval in...
BC Week In Review | Feb 16, 2018
Clinical News

pSivida reports Phase III data for Durasert in posterior segment uveitis

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) reported additional data from a Phase III trial in 153 patients with chronic, non-infectious posterior segment uveitis showing that intravitreal Durasert significantly reduced the recurrence of uveitis in the study eye...
BioCentury | Jan 6, 2018

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
BC Week In Review | Jul 13, 2017
Clinical News

pSivida submits MAA to EMA for Durasert

pSivida Corp. (NASDAQ:PSDV; ASX:PVA) submitted an MAA to EMA for Durasert to treat posterior segment uveitis. The company says it is in discussions to out-license the 3-year sustained-release fluocinolone acetonide treatment, and hopes to pin...
BioCentury | Jul 8, 2017

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | Apr 7, 2017

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Dec 31, 2016

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
BC Week In Review | Sep 5, 2016
Clinical News

Durasert screw implant: Phase I/II started

The Hospital for Special Surgery began an open-label, U.S. Phase I/II trial to evaluate sustained-release dexamethasone delivered via a screw implant in 1 knee in 6 patients. The implant consists of a screw implant designed...
BC Week In Review | Jun 8, 2015
Company News

pSivida deal

pSivida said an undisclosed global pharmaceutical company will evaluate pSivida’s Durasert bioerodible implantable delivery device system for undisclosed ophthalmic products from the pharma. The company declined to disclose details. pSivida Corp. (NASDAQ:PSDV;ASX:PVA), Watertown, Mass.  ...
Items per page:
1 - 10 of 18